Biological
UB-421 clinical trials
Also written UB-421 and dB4C7 mAb.
- studies test it
- 12
- open now
- 4
- in phase 3
- 2
- first study started
- 2015
Keep track of what changes. Save the UB-421 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
United BioPharma (9) · UBP Greater China (Shanghai) Co., Ltd (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses UB-421 is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral ReservoirNot yet recruitingPhase 2UBP Greater China (Shanghai) Co., LtdNCT04985890Written as UB-421
- UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 InfectionNot yet recruitingPhase 3United BioPharmaNCT04406727Written as UB-421
- The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 PatientsNot yet recruitingPhase 2UBP Greater China (Shanghai) Co., LtdNCT04404049Written as UB-421(25 mg/kg) Q2W
- Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected AdultsNot yet recruitingPhase 1United BioPharmaNCT04620291Written as UB-421 SC
- A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 InfectionWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05582694Written as UB-421
- To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected AdultsWithdrawnPhase 3United BioPharmaNCT03149211Written as UB-421
- Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive PatientsCompletedPhase 1United BioPharmaNCT04620304Written as UB-421 SC(dB4C7C22-6 mAb)
- UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection PatientsStatus unknownPhase 2United BioPharmaNCT03164447Written as UB-421
- A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV ReservoirsCompletedPhase 2United BioPharmaNCT05056974Written as UB-421
- The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 PatientsCompletedPhase 2United BioPharmaNCT03743376Written as UB-421(25 mg/kg) Q2W
- the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 PatientsWithdrawnPhase 2United BioPharmaNCT04041362Written as UB-421
- To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected AdultsCompletedPhase 2United BioPharmaNCT02369146Written as UB-421
Codes
What other systems call UB-421 · ClinicalTrials.gg INT001090
- MeSH (NLM) C000630912UB-421Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4180O0RM6KSEMZUVOLIMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630912 | UB-421 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4180O0RM6K | SEMZUVOLIMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.